A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

1,504

Participants

Timeline

Start Date

July 10, 2023

Primary Completion Date

July 16, 2024

Study Completion Date

July 16, 2024

Conditions
Influenza
Interventions
BIOLOGICAL

mRNA-1018 for H5N8

Sterile liquid for injection

BIOLOGICAL

mRNA-1018 for H7N9

Sterile liquid for injection

BIOLOGICAL

mRNA-1018 for H5 Only

Sterile liquid for injection

BIOLOGICAL

mRNA-1018 for H7 Only

Sterile liquid for injection

BIOLOGICAL

mRNA-1018 for H5 Only-CG

Sterile liquid for injection

Trial Locations (27)

31406

Velocity Clinical Research, Savannah

33024

CenExel RCA, Hollywood

48076

DM Clinical Research, Southfield

66219

Johnson County Clin-Trials, Lenexa

68510

Velocity Clinical Research, Lincoln

77375

DM Clinical Research, Tomball

77478

DM Clinical Research, Sugar Land

84095

J. Lewis Research, Inc/Jordan River Family Medicine, South Jordan

02818

Velocity Clinical Research Providence, East Greenwich

NE1 4LP

Royal Victoria Infirmary, Newcastle upon Tyne

SO16 6YD

Southampton General Hospital, Southampton

B15 2TH

University Hospitals Birmingham, Birmingham

BD9 6RL

Bradford Teaching Hospitals NHS Foundation Trust, Bradford

Bs2 8DX

University Hospitals, Bristol

CF14 4XW

Cardiff and Vale University, Cardiff

M6 8HD

Northern Care Alliance, Salford

TR1 3LJ

Royal Cornwall Hospital, Truro

LL13 7YP

North Wales Clinical Research Centre, Wrexham

NR4 7UQ

Quadram Institute NNUH CRF, Norwich

NN17 2UR

Lakeside Healthcare Research Unit, Corby

EH4 CXU

Western Hospital Edinburgh, Edinburgh

NW3 2QG

Royal Free Hospital, London

SE1 7EH

Guy's and St Thomas' NHS Foundation Trust - St Thomas' Hospital, London

SW10 9NH

Chelsea and Westminster Hospital, London

SW17 ORE

St Georges Vaccine Institute Cranmer Terrace, London

W1T 7HA

University College London Hospitals NHS Foundation Trust, London

N12 8BU

Velocity Clinical Research, North Finchley

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY